Impact of metformin on immunological markers: Implication in its anti-tumor mechanism
Publication in refereed journal


Times Cited
Altmetrics Information
.

Other information
AbstractMetformin, an anti-hyperglycemic drug, has been known to have antitumor properties for around 15 years. Although there are a number of reports attributing the antitumor function ofmetformin to its impact on energy homeostasis and oxygen re-distribution in tumor microenvironment, detailed mechanisms remain largely unknown. In the past several years, there is an increasing number of publications indicating that metformin can affect various immunological components including lymphocytes, macrophages, cytokines and several key immunological molecules in both human and animal studies. These interesting results appear to be in line with emerging data that suggest associations between immune responses and energy homeostasis/oxygen redistribution, which may explain effective impacts of metformin on immunotherapies against autoimmune diseases as well as cancers. This review article is to analyse and discuss recent development in the above areas with aim to justify metformin as a new adjuvant for immunotherapy against human cancers. We hope that our summary will help to optimize the application of metformin for various types of human cancers.
Acceptance Date29/05/2020
All Author(s) ListGeorge G Chen, Peter YM Woo, Stephanie CP Ng, George KC Wong, Danny TM Chan, CA van Hasselt, Michael CF Tong, WS Poon
Journal namePharmacology and Therapeutics
Year2020
Month9
Volume Number213
PublisherElsevier
Article number107585
ISSN0163-7258
LanguagesEnglish-United Kingdom
KeywordsMetformin, Cancers, Immune system, Immunotherapy

Last updated on 2021-21-04 at 23:33